A whole-body mathematical model of cholesterol metabolism and its age-associated dysregulation
© Mc Auley et al.; licensee BioMed Central Ltd. 2012
Received: 28 February 2012
Accepted: 21 September 2012
Published: 10 October 2012
Global demographic changes have stimulated marked interest in the process of aging. There has been, and will continue to be, an unrelenting rise in the number of the oldest old ( >85 years of age). Together with an ageing population there comes an increase in the prevalence of age related disease. Of the diseases of ageing, cardiovascular disease (CVD) has by far the highest prevalence. It is regarded that a finely tuned lipid profile may help to prevent CVD as there is a long established relationship between alterations to lipid metabolism and CVD risk. In fact elevated plasma cholesterol, particularly Low Density Lipoprotein Cholesterol (LDL-C) has consistently stood out as a risk factor for having a cardiovascular event. Moreover it is widely acknowledged that LDL-C may rise with age in both sexes in a wide variety of groups. The aim of this work was to use a whole-body mathematical model to investigate why LDL-C rises with age, and to test the hypothesis that mechanistic changes to cholesterol absorption and LDL-C removal from the plasma are responsible for the rise. The whole-body mechanistic nature of the model differs from previous models of cholesterol metabolism which have either focused on intracellular cholesterol homeostasis or have concentrated on an isolated area of lipoprotein dynamics. The model integrates both current and previously published data relating to molecular biology, physiology, ageing and nutrition in an integrated fashion.
The model was used to test the hypothesis that alterations to the rate of cholesterol absorption and changes to the rate of removal of LDL-C from the plasma are integral to understanding why LDL-C rises with age. The model demonstrates that increasing the rate of intestinal cholesterol absorption from 50% to 80% by age 65 years can result in an increase of LDL-C by as much as 34 mg/dL in a hypothetical male subject. The model also shows that decreasing the rate of hepatic clearance of LDL-C gradually to 50% by age 65 years can result in an increase of LDL-C by as much as 116 mg/dL.
Our model clearly demonstrates that of the two putative mechanisms that have been implicated in the dysregulation of cholesterol metabolism with age, alterations to the removal rate of plasma LDL-C has the most significant impact on cholesterol metabolism and small changes to the number of hepatic LDL receptors can result in a significant rise in LDL-C. This first whole-body systems based model of cholesterol balance could potentially be used as a tool to further improve our understanding of whole-body cholesterol metabolism and its dysregulation with age. Furthermore, given further fine tuning the model may help to investigate potential dietary and lifestyle regimes that have the potential to mitigate the effects aging has on cholesterol metabolism.
Lipid metabolism has a key role to play in human longevity and healthy ageing. This has been emphasized by recent genetic studies examining the lipoprotein phenotype in individuals with exceptional longevity[1, 2]. It is highly probable such subjects with exceptional longevity and favourable lipoprotein profiles have avoided CVD. CVD is the primary cause of mortality in developed countries, with almost 40% of males and 30% of females in the United Kingdom over the age of 85 years living with the condition. Of the components of lipid metabolism, elevated LDL-C has consistently stood out as a risk factor for CVD. This cholesterol sub-fraction has been connected to atherosclerosis, a process regarded as the underlying pathogenesis for coronary heart disease (CHD) and stroke, the leading forms of CVD. Studies have repeatedly demonstrated that regardless of physical activity levels and nutritional status, LDL-C has been shown to rise with age in both males and females in a diverse range of groups[6, 7]. Understanding why LDL-C rises with age is complex; nevertheless rodent studies have indicated that increases in intestinal cholesterol absorption or possibly a decrease in the plasma clearance rate of LDL-C may have a mechanistic role to play[8–10]. In this paper we examine the hypothesis that these two mechanisms are central to understanding why LDL-C increases with age. To test this hypothesis a number of steps were required. Firstly, it was necessary to study both intestinal cholesterol absorption and LDL-C plasma clearance within an integrative framework which incorporated the other fundamental biological components of this complex system[11, 12]. This required incorporating the interactions of the individual elements of this system. Secondly, it was important to investigate changes both to intestinal cholesterol absorption and LDL-C clearance over an extended period of time. Clearly it would have been difficult to test our hypothesis within this framework using conventional in vivo or in vitro techniques as such approaches can be resource intensive, expensive, time consuming, unpractical and potentially unethical. Furthermore, whole-body cholesterol metabolism is a complex system with a variety of non-linear interactions among its various components, including both positive and negative feedback and complex crosstalk between elements such as cholesterol synthesis and absorption.
Utilizing a mechanistic mathematical model offered an alternative means of overcoming these difficulties and presented a cheap, ethical and practical way of investigating our hypothesis. However, as existing computational models of cholesterol metabolism were either of an intracellular nature, lipoprotein kinetic focused, or compartmental in nature, they failed to incorporate the ageing process or address the holistic nature of our question and were thus determined to be unsuitable[15, 16]. Consequently we constructed a whole-body mathematical model of cholesterol metabolism which was used to explore changes to both the rate of intestinal cholesterol absorption and the hepatic rate of clearance of LDL-C from the plasma. The model showed that of these two mechanisms, changes to the rate of LDL-C removal from the plasma with age had the most significant effect on cholesterol metabolism. The model was constructed using a series of coupled ordinary differential equations (ODEs). Additionally, the model was coded in the systems biology markup language (SBML) format and submitted to the Biomodels database to facilitate its updating and future exchange[17, 18]. To build the model a wide variety of data was used including previously published data from a range of fields such as molecular biology, nutrition, physiology and biochemistry.
Whole-body cholesterol metabolism
Cholesterol has a vital role to play in the human body. It is a key constituent of all cell membranes being involved in membrane fluidity; it is the precursor of steroid hormones which control a range of physiological functions, and bile salts, which are necessary for the intestinal absorption of cholesterol, fats and lipid soluble vitamins[19, 20]. The mechanisms underpinning cholesterol metabolism interact to preserve the balance of cholesterol in the body. This balance is maintained by coordinated interactions between cholesterol absorption, excretion and synthesis.
Intake, absorption and excretion
Cholesterol from both the diet and bile is taken up by the small intestine daily. Cholesterol absorption is an inefficient process and can vary significantly from person to person. The percentage of cholesterol absorbed in healthy subjects (both male and female) is in the range of 29-80%. The heterogeneity in cholesterol absorption has been attributed to its complexity, which involves a large number of enzymes and transport proteins in a multi-step process, however the way these mechanisms interact to regulate absorption efficiency remains unknown. It is clear that during digestion, bile acids are released from the liver and gall bladder into the intestine and as cholesterol is practically insoluble in aqueous environments, the bile acids serve to create lipid micelles. The micelles are then transported to the brush border of jejunal enterocytes, where the cholesterol is transferred into the enterocytes. At this point the story becomes nebulous, as the mechanism(s) by which micellar cholesterol is absorbed through the brush border membranes independent of bile salt uptake remains a mystery. A long standing hypothesis suggests that cholesterol absorption occurs by passive diffusion down a concentration gradient[24, 25]. However, recent evidence supports the hypothesis that protein facilitated mechanisms are involved in cholesterol uptake by the enterocyte[26, 27]. When cholesterol is inside enterocytes, it has been suggested that it can be transported back to the intestinal lumen by a class of membrane proteins known as adenosine triphosphate binding cassette transporters. It has been proposed that these transporters may serve to efflux cholesterol from the enterocyte back into the intestinal lumen for excretion. Although the precise mechanisms of cholesterol absorption are not yet fully understood, it is known that cholesterol not transported back to the intestinal lumen is esterified in the enterocyte by acyl-CoA-cholesterol acyltransferase (ACAT), assembled and packaged, together with triglycerides, into chylomicrons. Chylomicrons are just one of many lipid carriers, known as lipoproteins, found in the circulation of mammals. According to their density, lipoproteins are categorised as chylomicrons, very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density lipoproteins (LDL) and high density lipoproteins (HDL). Chylomicrons transport absorbed cholesterol via the lymph to the liver.
The liver and whole-body cholesterol metabolism
The liver is the central organ involved in cholesterol metabolism. It is actively involved in the uptake of cholesterol from lipoproteins, is an important site for de novo synthesis and is capable of storing cholesterol as esters after esterification by ACAT. Furthermore, it is involved in the secretion of cholesterol-containing lipoproteins and is the sole organ capable of removing excess cholesterol from the body, either by secretion into bile or by conversion into bile acids. Bile acids are synthesised from cholesterol in the liver and facilitate the solubilisation of cholesterol, a prerequisite for cholesterol absorption. Bile acids are released postprandially and will not solubilise dietary lipids unless above a critical concentration. The concentration gradient is generated by two factors. Firstly, bile acids are powerful acids that are impermeable to cell membranes. Secondly, the majority of bile acids are reabsorbed from the small intestine and return to the liver via the portal vein, where they are taken up by hepatocytes and re-secreted into bile. The conservation of bile acids by active absorption from the small intestine results in a hepatic pool of bile acids that cycles several times with each meal. In humans, the bile acids circulate between six and 10 times per day, while around 400 mg of bile acids is lost daily through faecal excretion. A decreased return of bile acids to the liver is compensated for by increased de novo synthesis from cholesterol in order to maintain the bile salt pool. Cholesterol not converted to bile acids or secreted into bile can be released from the liver into the circulation and transported to peripheral tissue. The liver secretes VLDLs and on entering the circulation VLDLs are hydrolysed by lipoprotein lipase (LPL), leading to the formation of VLDL remnants and IDLs. IDLs are either taken up by the liver or further hydrolysed to LDLs, which are the main cholesterol carrier in the blood. LDL is taken up by the liver or by peripheral cells, either independently or via the LDL-receptor (LDLR). Expression is high in the liver but LDLRs are also expressed in peripheral tissue[36, 37]. Hepatic LDLR (HLDLR) expression is transcriptionally regulated in response to intracellular cholesterol levels.
Reverse cholesterol transport
The flux of cholesterol from peripheral tissue to the liver is known as reverse cholesterol transport (RCT). This pathway plays a vital role in maintaining cholesterol balance, with its action resulting in the movement of cholesterol from peripheral tissue to the liver. Consequently RCT presents the only route for excess cholesterol generated in peripheral tissue to be eliminated from the body. HDL plays a crucial part in RCT[40, 41]. HDL synthesis takes place in the liver and intestine, commencing with the generation of nascent particles, small discoidal structures lacking cholesterol. HDL acquires free cholesterol from the cell membranes of several tissues, which is esterified by the action of lecithin:cholesterol acyltransferase (LCAT), resulting in cholesteryl ester-rich, mature HDL particles. The transport of high density lipoprotein cholesterol (HDL-C) to the liver may follow several routes. In the presence of the enzyme cholesteryl ester transport protein (CETP), a portion of cholesterol esters from the HDL particle can be redistributed to other lipoproteins (e.g. VLDL and LDL) in exchange for triglyceride. This cholesterol is delivered back to the liver via the LDLR. An alternative route involves the mature HDL particle binding directly to scavenger receptors BI (SR-BI) on the liver.
Almost all the tissues in the body are capable of synthesizing cholesterol from acetyl-Co enzyme A (CoA) in a series of enzyme-mediated steps that are mainly restricted to the endoplasmic reticulum (ER). The major rate-controlling enzyme in this pathway is 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase. Cholesterol homeostasis is regulated in two ways, firstly, when the content of unesterified cholesterol in cells increases, the expression of the LDLR protein decreases. Furthermore, two key enzymes involved in cholesterol synthesis are repressed, thus, any subsequent increase in cellular cholesterol diminishes. When cholesterol levels fall, these pathways are reactivated[38, 44, 45].
Dysregulation of cholesterol metabolism with age
The interaction between cholesterol absorption, synthesis, and excretion maintains whole- body cholesterol metabolism. A change to any of them can significantly influence the others. For example, numerous studies have shown that inhibition of cholesterol synthesis results in increased intestinal cholesterol absorption[46, 47]. The close interaction between absorption and synthesis in maintaining cholesterol balance is consolidated by studies, which have shown that interference with cholesterol absorption is associated with increased cholesterol synthesis. Dysregulation of cholesterol metabolism can lead to high levels of LDL-C, while population studies have consistently demonstrated that LDL-C rises with age in both males and females. The reason for an increase in LDL-C in so many individuals across both genders remains unknown. Furthermore, the intrinsic mechanisms that contribute to the rise in LDL-C with age remain incomplete; however a picture is beginning to emerge of potential candidates. A significant finding was the discovery that there is a gradual reduction in the rate of clearance of LDL-C from the circulation with age[48–50]. Adding further to this is the evidence that the number of hepatic LDLRs (HLDLRs) diminish with age in certain species[10, 50]. Additionally, it has been reported that there is an increase in intestinal cholesterol absorption efficiency with age in rats[8, 51]. However, to date no single intrinsic mechanism or combination of intrinsic mechanisms has conclusively been attributed to the rise in LDL-C with age. Consequently our whole-body mathematical model investigated the hypothesis that age-related changes to the rate of intestinal cholesterol absorption and the rate of removal of LDL-C from the plasma could be responsible for the rise in LDL-C with age in humans.
Predictive capability of the model
Sensitivity analysis-cholesterol absorption
List of species, their abbreviations and their initial values
Intestinal bile salts
Intestinal cholesterol synthesis
0 (Source Species)
Intestinal nascent high density lipoprotein synthesis
0 (Source species)
Excreted bile salts
Hepatic Tissue Species
Hepatic cholesterol synthesis
0 (Source Species)
Hepatic nascent HDL synthesis
0 (Source Species)
Hepatic bile salt pool
Hepatic free cholesterol
Hepatic low density lipoprotein receptors
100 (Theoretical value to represent the number of hepatic LDL receptors )
Hepatic low density lipoprotein receptor synthesis
600 (Source species)
Hepatic LDL receptors degradation
0 (Sink species)
Hepatic cholesterol esters
Scavenger receptor class B type 1
100 (Theoretical value to represent concentration of SRB1 receptors)
Peripheral Tissue Species
Peripheral low density lipoprotein receptors
100 (Theoretical value)
Peripheral low density lipoprotein receptors synthesis
575.16 (Source species)
Peripheral low density lipoprotein receptors degradation
0 (Sink species)
Peripheral free Cholesterol
Peripheral cholesterol esters
Peripheral steroid synthesis
0 (Sink species)
Peripheral cholesterol synthesis
Low density lipoprotein cholesterol
High density lipoprotein cholesterol
Nascent high density lipoprotein
100 (Theoretical value to represent the initial number of Nascent HDL)
Very low density lipoprotein cholesterol
Intermediate density lipoprotein cholesterol
Cholesteryl ester transfer protein
100 (Fixed boundary condition)
100 (Fixed boundary condition)
Hormone sensitive Lipase
100 (Fixed boundary condition)
100 (Fixed boundary condition)
Hepatic Tissue Species and Peripheral Tissue
Cholesterol ester hydrolase
100 (Fixed boundary condition)
acyl coenzyme A: cholesterol acyltransferase
100 (Fixed boundary condition)
Summary of the reactions and parameter values used in the model
Bile salt release
Hepatic return of bile salts
Bile salt excretion
8.56 × 10-1
Bile salt synthesis
5.29 × 10-4
5.29 × 10-4
Intestinal Nascent HDL synthesis
5 × 10-4
Hepatic cholesterol storage
Release of stored Hepatic cholesterol
Hepatic Nascent HDL Synthesis
5 × 10-2
VLDL cholesterol formation
1.6 × 10-2
Synthesis of hepatic LDL receptors
Hepatic LDL receptors degradation
1 × 10-3
VLDL cholesterol hepatic reuptake
4.96 × 10-3
IDL cholesterol formation
4.3 × 10-1
IDL cholesterol hepatic reuptake
5.4 × 10-2
LDL cholesterol formation
3.8 × 10-1
Hepatic LDL receptors uptake of LDL-cholesterol
6.80 × 10-2
Hepatic receptor independent uptake of LDL-cholesterol
5.0 × 10-3
Peripheral LDL receptors uptake of LDL-cholesterol
6.75 × 10-3
Peripheral independent uptake of LDL-cholesterol
5.0 × 10-6
Synthesis of peripheral LDL receptors
Peripheral LDL receptors degradation
1 × 10-2
Peripheral cholesterol storage
1.75 × 10-2
Release of stored peripheral cholesterol
1.07 × 10-1
Peripheral steroid production
5 × 10-4
HDL cholesterol formation
1.5 × 10-5
CETP mediated transfer of cholesterol to VLDL from HDL
10 × 10-3
CETP mediated transfer of cholesterol to LDL from HDL
1 × 10-3
Reverse cholesterol transport
5.0 × 10-2
Maximum rate of intestinal cholesterol synthesis
1 × 102
Intestinal cholesterol synthesis threshold
3.120 × 102
Sensitivity of intestinal cholesterol synthesis
Maximum rate of biliary cholesterol release
2 × 103
Biliary cholesterol release threshold
5.55 × 104
Sensitivity of the feedback equation for biliary cholesterol
Maximum rate of hepatic cholesterol synthesis
5 × 102
Sensitivity of hepatic cholesterol synthesis
Hepatic cholesterol synthesis threshold
9.39 × 104
Maximum rate of peripheral cholesterol synthesis
5 × 102
Peripheral cholesterol synthesis threshold
8.0342 × 104
Sensitivity of peripheral cholesterol synthesis
Sensitivity analysis-dietary cholesterol
A literature review using PubMed revealed the existence of almost 200 publications containing information relating to the response of plasma cholesterol to dietary cholesterol feeding. These investigations were performed in both young and old individuals. Importantly among these publications, a meta-analysis by McNamara (2000) revealed that in response to increased levels of dietary cholesterol, plasma cholesterol plateaus at high levels of cholesterol intake. The meta-analysis by McNamara also reported that the total plasma cholesterol response to dietary cholesterol is 0.023 mg/dL per mg/day cholesterol increase (Figure1, graph A). Of this, 0.019 mg/dL is in the LDL-C fraction. Therefore, for each 100 mg/day increase in dietary cholesterol intake in the model, a 1.9 mg/dL increase in LDL-C was expected. Importantly, McNamara reported that this increase is independent of other types of lipid in the diet and the baseline plasma cholesterol level. Therefore, the model was exposed to a decrease of 200 mg/day and increases of up to 700 mg/day of dietary cholesterol (Figure1, graphs A-C). A ≈10 mg/dL increase in LDL-C was observed for every 100mg increase in dietary cholesterol which was 8mg greater than the value predicted in the meta-analysis by McNamara. We also conducted a sensitivity analysis of the parameter k 1 to highlight the different steady-state levels of LDL-C for various intakes of dietary cholesterol (Figure1, graphs E&F and Additional file1). No increase in HDL-C was observed in response to changes in dietary cholesterol.
Hypothesis testing- ageing and cholesterol absorption/LDL-C plasma removal
Aging results in a rise in LDL-C in both sexes (Figure2, graphs C and D). The reason(s) for an increase in LDL-C in so many individuals across both genders remains unknown and the issue is the subject of debate as nutritional status and physical activity levels may differ within the population sample. The intrinsic mechanism(s) that contribute to the rise in LDL-C with age remain incomplete; however a picture is beginning to emerge of potential candidates. As mentioned previously, rodent studies have shown that cholesterol absorption efficiency increases markedly with aging[8, 21]. It was also mentioned that there is a gradual reduction in the rate of clearance of LDL-C from the circulation with age in rodents. Adding further to this is the evidence that the number of hepatic LDLRs diminish with age in certain species. When cholesterol absorption efficiency was increased in 10% increments between 50% and 80% by age 65 years, 12, 24 and 34mg/dL increases respectively, in LDL-C were observed (Figure2, graph A). Next, reducing the number of hepatic LDL receptors (HLDLRs) was investigated. The number of HLDLRs was reduced in the range 90–50 by age 65 years. This was done by gradually decreasing the rate of synthesis k hrs . This had a significant effect on the model as LDL-C raised by 116,76,49,26 and 11mg/dL respectively (Figure2, graph B). A parameter scan of k hrs was also conducted (Figure2, graph E).
We have constructed a whole-body mathematical model of cholesterol metabolism using data from a wide variety of sources and integrated this data within a series of coupled ODEs. Previous computational models have focused on the intracellular regulation of cholesterol metabolism[16, 53] or have focused on the metabolic fate of a particular lipoprotein or their receptor mediated endocytosis[54, 55], while other mathematical models of lipid metabolism have centred on compartmental approaches, where by lipoproteins are represented by compartments. Our model attempts to include all the major components of whole-body cholesterol balance and to our knowledge is the first model of its type built using such a framework. Our model provides an insight into the complex interplay of cholesterol metabolism with the aging process. The model has many areas that require further development, however, when the model progresses in the future it would be worthwhile to investigate how changes to different combinations of parameters affect the overall behaviour of the system, as the model indicates that the dysregulation of cholesterol metabolism with age may involve perturbations to several components of this system. In tandem with investigating changes to combinations of parameters, the model may also be used to investigate combination therapy that may help to mitigate the effects aging has on cholesterol metabolism. For example, it would be straightforward to include hypothetical interventions that investigate different dietary regimes and also include the effects of variations in physical activity. For example, based on available literature the simple assumption could be made that consuming 3 g/day of fibre reduces cholesterol absorption by 15%[57, 58]. Therefore, the parameters could be adjusted accordingly to reflect this. Similarly the effect of consuming plant sterols, which are known to reduce cholesterol absorption[59, 60] could easily be investigated, as consumption of 1.8 to 2.0 g/day of plant sterols has been shown to lower both total and LDL-C concentrations by 10% to 15%, respectively in a variety of different population groups[61–63]. Thus, this could be investigated by making alterations to the rate of cholesterol absorption in the model.
As mentioned previously the model is by no means the finished product and several assumptions were made during the building of the model, which were necessary as considerable uncertainty still surrounds cholesterol metabolism. For example, in the majority of cases the functional form that best describes a reaction remains unknown. We did however include a number of feed-back and feed-forward equations to describe the behaviour of cholesterol and bile salt synthesis as these are known to be subject to this type of action. At steady state, parameter values attempted to reflect a generic normolipididemic 20 year old male. Although parameter values were chosen for the model from available published literature, the ranges of parameter values are quite broad; however, given the nature and diversity of the literature used this was unavoidable. On certain occasions, parameter values simply did not exist, therefore reasonable values were chosen based on the published literature. An area of the model that could be developed further in the future is the kinetic parameters of the various enzymes involved in a number of the reactions. Presently, most of these enzymes have arbitrary values of 100 assigned to them to indicate that they have ‘normal’ enzymatic activity. In the future it would be worthwhile to use a resource such as BRENDA to amend these enzymes to include km and kcat values. Despite these limitations it is hoped that in the future the model will prove to be a useful tool for testing nutritional and lifestyle interventions that would be difficult, challenging or perhaps unethical to conduct using convention means.
Building the model has highlighted priorities for future experimental work, for example the need for experimentalists to work closely with computational modellers in order to generate appropriate quantitative data that is of benefit to systems biology models such as this one. Such data could be used to expand and enhance our model leading to a better understanding of cholesterol metabolism, particularly the interrelationship between cholesterol synthesis and absorption. This improved model could be used to gain additional insights into the factors associated with cholesterol metabolism that help to confer increased longevity and healthy aging. Appropriate dietary intervention strategies based on such models could be used to decrease the risk of CVD and prolong healthy aging. Models could be tailored for an individual’s dietary, biochemical, genetic and social circumstances and as such models can be coded in SBML they would be relatively easy to extend, enhance and improve as more quantitative data becomes available. Furthermore, it would be worthwhile combining our model with existing models, such as that of atherosclerosis progression. The portable nature of SBML also makes this a very realistic possibility, especially if models that are being merged have been designed using SBML[66, 67]. Moreover, the model could be used to investigate crosstalk between cholesterol metabolism and fatty acid metabolism.
From the evidence presented in this paper it is clear that cholesterol metabolism is a complex multi-component system. Changes to this multi-component system as a result of the ageing process can lead to high levels of plasma cholesterol particularly LDL-C. There is an indisputable link between elevated levels of LDL-C and the risk of developing atherosclerosis, with population studies indicating that LDL-C rises with age in both sexes in a large number of individuals[5, 68, 69]. It is therefore unsurprising that recent genetic studies have associated lipid metabolism with longevity as it is apparent that maintaining cholesterol balance is vital to cardiovascular health[1, 2, 70, 71].
We developed a whole-body computational model to investigate the hypothesis that an increase in the rate of cholesterol absorption and a reduction in the rate of removal of LDL-C from the plasma were integral to understanding the dysregulation of cholesterol metabolism with age. We were of the opinion that existing models of cholesterol metabolism were limited and could not offer a sufficiently deep understanding of how an entire biological system changes with age, thus in this work a conscious effort was made to represent the interactions throughout the body. Results from the sensitivity analysis of the model indicated that the model requires further fine-tuning in the future before it could be used as a comprehensive tool for predicting changes to LDL-C in response to dietary cholesterol/fats and intrinsic aging. None the less we used the model to investigate aging and it demonstrated that changes to the rate of removal of LDL-C to half its original value at age 65 years resulted in a 116 mg/dL rise in this cholesterol sub fraction, which is intimately connected with CVD. The model contrasts with other models of cholesterol metabolism in that it is implemented in a whole-body fashion and provides a template for building a quantitative systems level understanding of cholesterol metabolism and its interaction with aging. In the future the model could contribute to a better understanding of cholesterol metabolism so that the wider population could benefit in the same way as those individuals with exceptional longevity have from an altered lipid profile.
Deciding on model structure and the rationale for a whole-body approach
Historically, mathematical modelling has been used to investigate various aspects of both cholesterol and more generally lipid metabolism; however to our knowledge no model to date has been implemented to investigate cholesterol metabolism mechanistically within a whole- body framework, with the goal of understanding how intrinsic age-related biological changes affect this crucial biological system. In order to appreciate the rationale underpinning the whole-body approach that we adopted, it is worthwhile examining some of the models of cholesterol metabolism that have been developed previously. Additionally, it is worth exploring why these were unsuitable for this work. In general these models can be divided into three types; intracellular models of the cholesterol homeostasis genetic regulatory pathway; models of lipoprotein dynamics, and compartmental models. If we take the gene network approach, a recent version involved a boolean network model that assigned 33 different components of intracellular cholesterol homeostasis a boolean value. Simulations then led to the representation of intracellular cholesterol homeostasis as a boolean vector with each coordinate of the system denoting a biological species of the pathway. It is easy to appreciate the utility of this approach as a means of better understanding the functioning of a gene regulatory network; however this strategy is not a mechanistic approach. It is primarily a state based representation of intracellular gene activity; therefore it is limited as it does not include the different biological compartments involved in cholesterol metabolism, such as absorption, and hepatic/peripheral cholesterol synthesis. Nor does it account for the synthesis of the various lipoproteins such as VLDL, IDL, LDL and their subsequent interactions with one another and with receptors both hepatically and peripherally. Finally, and significantly for this work it is difficult to imagine such models being able to test a biological hypothesis that centres on three factors, the aging process, cholesterol absorption and the removal of LDL-C from the plasma.
If mathematical models focused on lipoprotein kinetics are examined; one discovers a wide variety of models that have represented varying degrees of cholesterol metabolism and have centred to a large extent on the dynamics of the LDL receptor. Examples of such models go back as far as the early 1980s when Goldstein et al. presented a theoretical study of the interaction of LDL receptors with coated pits[72, 73]. These were followed by other models of the same process or more recent slight adaptations of this process. These models have been beneficial from the point of view of elucidating the underlying dynamics which describe the interaction of LDL with its receptor and the associated underlying kinetics of this process. However, as with the intracellular models, these models focus on one particular, isolated aspect of cholesterol metabolism and do not portray the entire picture which is that cholesterol metabolism involves the coordinated action of several different biological systems operating in unison throughout the entire body.
The final approach that will be discussed is the compartmental methodology. Compartmental models, as the name suggests, contain a number of compartments, each containing a well mixed material. Each compartment has a number of connections leading into it and out of it. Biological material can flow from one compartment to another, and it can be added from the outside through a source, or it can be removed through a sink. Such systems exchange material with each other following certain rules. These models have advantages such as being able to examine in some detail the interaction of lipoproteins and their derivatives. The major limitation of these models is that they are not based on underlying biological mechanisms; rather exchange rates are based on experimental inferences. Therefore, as with the previous approaches this method is also unsuitable for representing a mechanistic whole-body of cholesterol metabolism.
In order to overcome the limitations of the approaches that have been discussed, it was decided to represent cholesterol metabolism with the aid of biological compartments that represented their real-world biological counterparts. The compartments contained quantitative details of the different forms of cholesterol. These forms are present in very high numbers (e.g. intestinal, hepatic and peripheral cholesterol is present in grams). This means that a stochastic approach would not offer significant benefits, as the intrinsic stochasticity in the system is negligible, and so a deterministic model was considered more appropriate to represent these species and their interactions. In order to implement this deterministic solution, we created a series of ordinary differential equations that were coupled and numerically integrated. This type of approach has previously been shown to be eminently suitable both for representing mechanistic biological reactions and for dealing with the time dimension associated with modelling the aging process. In order to build the ODEs, we first needed to concisely represent the compartments and the fundamental components of whole-body cholesterol metabolism diagrammatically.
Construction of a network diagram
Rationale for reaction forms
The assumption was made that a large number of the reactions are of a first-order nature, where the rate of the reaction is directly proportional to the concentration of one of the reactants. This assumption was made to facilitate the evaluation of the model based on steady states and to allow for the determination of parameters when the model was compared to experimental data, moreover the reaction form that best describes a large number of these remains unknown. ODEs were constructed in an incremental fashion to meet certain steady states, eventually giving rise to a unified series of coupled ODEs and ultimately a whole-body mathematical model representing a generic twenty year old male. The model was built using MathSBML. MathSBML is a software package that has been designed to work with Mathematica (version 5.2), a pre-existing commercial software package developed to perform numeric, algebraic, graphical and many other tasks. In addition the software tool Copasi was used to perform some of the parameter scans and steady state examinations of the model. The next section outlines the assembly of the ODEs and the biological functions that lie at their core. Additionally, the reasoning for the inclusion of each of the species in Figure4 will be detailed along with the quantitative data that was used to make inferences about each of the steady states that these species gave rise to.
As whole-body cholesterol metabolism was being dealt with, it was important first to include the dietary intake of cholesterol. According to Henderson et al. the average amount of cholesterol ingested daily in the UK by a male is 304 mg/day. Cholesterol intake was assigned the rate k1 and set at an initial value of 1. While dietary cholesterol [DC] had its initial condition set to a fixed value of 304.
Breakdown of whole-body cholesterol synthesis
Whole-Body (70 kg man)
441 mg/day (70% of whole-body)
49 mg/day(10% of peripheral)
Hepatic biliary cholesterol release
Estimating the steady-state levels of cholesterol in each compartment
Calculating the steady-state level of intestinal cholesterol
The steady-state level of intestinal cholesterol
Weight of intestine
Number of 100 g segments in intestine
Total amount of cholesterol equals the number of 100 g segments times 150 mg
Bile salts- hepatic synthesis and enterohepatic circulation
Cholesterol absorption and excretion
Flux of cholesterol into and out of the small intestine on a daily basis
Amount in mg/day
Simulations of the mini model
Expansion of the mini model- further additions to the hepatic compartment
Outlining how the concentration of cholesterol in the liver was determined (Non obese subjects (n=19))
Mean free cholesterol
Mean esterified cholesterol
Total Hepatic Cholesterol
Molecular weight of cholesterol
Used to convert nmol to milligrams
44.6979 μg/mg or 0.0446979 mg/mg
7.1539 μg/mg or 0.0071532 mg/mg
Total free cholesterol
37.5447 μg/mg or 0.0375447 mg/mg
Size of Human Liver = 1.5 kg
0.0446979 *1500000=67046.85 mg total cholesterol
0.0071532 * 1500000=10792.80 mg of cholesterol esters
0.0375447*1500000=56317.5 mg of free cholesterol
These ODEs were added to the system and the model was re-parameterised by sequential adjustment of the parameters in order to bring both hepatic cholesterol esters and the hepatic pool of free cholesterol into a steady-state (Figure6, graphs B and C).
Hepatic release of very low density lipoprotein cholesterol
According to Glomset et al. the amount of cholesterol secreted hepatically in VLDL is considered to be in the region of 800 mg/day and could be as high as 3000 mg/day. Therefore, it was assumed that in the steady state ≈1000 mg/day of cholesterol was incorporated into VLDL. The rate of incorporation of cholesterol into VLDL was assumed to be proportional to the concentration of hepatic cholesterol and this reaction was assigned the rate constant k12.
The turnover of hepatic LDL receptors
It is known that a certain amount of VLDL-C is removed via HLDLRs. It was difficult to obtain quantitative data about this process; however the literature indicated that this is not the major route by which cholesterol re-enters the liver. It was therefore assumed that only a negligible amount of VLDL-C is taken up via this avenue (≈100 mg/day) and was assigned the rate constant k14.
Hepatic LDL receptor mediated removal of VLDL-C from the plasma
Parameterisation to establish the steady states of LDL-C, IDL-C VLDL-C
As the system had now increased in size significantly, further simulations were completed to establish the steady-state levels of the various species. Again the model was re-parameterized using the data outlined and the system numerically solved with MathSBML. After adjustment of the parameters LDL-C, IDL-C and VLDL-C entered steady states based on known literature values (Figures6, graphs D and E). It is important to note that the values of both the peripheral pool of free cholesterol (PFC) and PLDLRs were held at fixed arbitrary values of 100 to facilitate this process.
Further additions to the peripheral compartment
Calculation of cholesterol in the peripheral tissue
Remaining cholesterol in peripheral tissue
70000-3120= 66880 mg
10000 mg of stored cholesterol, which represents 14% of overall hepatic cholesterol
Assuming 14% is stored here: 14% of 66880=3963.2 mg
Peripheral free cholesterol
Reverse cholesterol transport and the final steps to a whole-body mathematical model
Based on current literature it was assumed that the production of HDL-C is dependent on three factors; the concentration of peripheral free cholesterol, the population of nascent HDL particles and the activity of the enzyme LCAT which has a role to play in the conversion of free peripheral cholesterol into cholesteryl esters which are then sequestered into the core of a lipoprotein particle, eventually making the newly synthesized HDL particle. The enzyme is bound to HDLs and LDLs in the blood plasma.
Updating of ODEs 5 and ODE6
Model exchangeability, SBML and submission to the Biomodels database
The model was coded into SBML using an export function in MathSBML (Additional file2). Unlike computer languages such as C, C++ and Java, SBML was not designed to be coded manually; instead a number of tools are available that automatically generate SBML. The code can then be exchanged between tools supporting SBML. In this case the model code was transferred into the software tool Copasi to facilitate parameter scanning. Please note that when the ODEs are integrated in Copasi using the initial conditions, LDL-C enters a slightly higher steady-state than it does with MathSBML. In addition the model was submitted to the Biomodels database http://www.ebi.ac.uk/biomodels-main/ to facilitate its updating and future exchange (MODEL1206010000).
We acknowledge Fotios Drenos, Daryl Shanley and Carole Proctor for their advice throughout the duration of this work. We also acknowledge Chris Packard for his advice on cholesterol metabolism. MT Mc Auley was funded by an EPSRC CASE studentship with Unilever PLC. The research was also supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University.
- Barzilai N, Atzmon G, Derby CA, Bauman JM, Lipton RB: A genotype of exceptional longevity is associated with preservation of cognitive function. Neurology. 2006, 67 (12): 2170-2175. 10.1212/01.wnl.0000249116.50854.65.View Article
- Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, Lipton R, Cheng S, Shuldiner AR: Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA. 2003, 290 (15): 2030-2040. 10.1001/jama.290.15.2030.View Article
- Capewell S, Allender S, Critchley J, Lloyd-Williams F, O’Flaherty M, Rayner M, Scarborough P: Cardio & Vascular Coalition Modelling the UK burden of Cardiovascular Disease to 2020:A Research Report for the Cardio & Vascular Coalition and the British Heart Foundation. British Heart Foundation. 2008
- Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986, 256 (20): 2835-2838. 10.1001/jama.1986.03380200073024.View Article
- Berliner J, Leitinger N, Watson A, Huber J, Fogelman A, Navab M: Oxidized lipids in atherogenesis: formation, destruction and action. Thromb Haemost. 1997, 78 (1): 195-199.
- Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkand BM, Schonfeld G, Jacobs D, Frantz ID: Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study. Circulation. 1980, 61 (2): 302-315. 10.1161/01.CIR.61.2.302.View Article
- Abbott RD, Garrison RJ, Wilson PW, Epstein FH, Castelli WP, Feinleib M, LaRue C: Joint distribution of lipoprotein cholesterol classes. The Framingham study. Arteriosclerosis. 1983, 3 (3): 260-272. 10.1161/01.ATV.3.3.260.View Article
- Hollander D, Morgan D: Increase in cholesterol intestinal absorption with aging in the rat. Exp Gerontol. 1979, 14 (4): 201-204. 10.1016/0531-5565(79)90020-2.View Article
- Wang DQ: Aging per se is an independent risk factor for cholesterol gallstone formation in gallstone susceptible mice. J Lipid Res. 2002, 43 (11): 1950-1959. 10.1194/jlr.M200078-JLR200.View Article
- Grundy SM, Vega GL, Bilheimer DW: Kinetic mechanisms determining variability in low density lipoprotein levels and rise with age. Arteriosclerosis. 1985, 5 (6): 623-630. 10.1161/01.ATV.5.6.623.View Article
- Hood L: Systems biology: integrating technology, biology, and computation. Mech Ageing Dev. 2003, 124 (1): 9-16. 10.1016/S0047-6374(02)00164-1.View Article
- Wang K, Lee I, Carlson G, Hood L, Galas D: Systems biology and the discovery of diagnostic biomarkers. Dis Markers. 2010, 28 (4): 199-207.View Article
- Kirkwood TBL, Boys RJ, Gillespie CS, Proctor CJ, Shanley DP, Wilkinson DJ: (2005) Computer Modeling in the Study of Aging, in S. N. Austad, E. J. Masoro (eds.): Computer Modeling in the Study of Aging. Handbook of the Biology of Aging. Academic. 2005, 334-357.View Article
- Homan R, Krause BR: Established and emerging strategies for inhibition of cholesterol absorption. Curr PharmDes. 1997, 3: 29-44.
- Goodman DS, Smith FR, Seplowitz AH, Ramakrishnan R, Dell RB: Prediction of the parameters of whole body cholesterol metabolism in humans. J Lipid Res. 1980, 21 (6): 699-713.
- Kervizic G, Corcos L: Dynamical modeling of the cholesterol regulatory pathway with Boolean networks. BMC Syst Biol. 2008, 2: 99-10.1186/1752-0509-2-99.View Article
- Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, Arkin AP, Bornstein BJ, Bray D, Cornish-Bowden A, et al.: The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics. 2003, 19 (4): 524-531. 10.1093/bioinformatics/btg015.View Article
- Li C, Donizelli M, Rodriguez N, Dharuri H, Endler L, Chelliah V, Li L, He E, Henry A, Stefan MI, et al.: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models. BMC Syst Biol. 2010, 4: 92-10.1186/1752-0509-4-92.View Article
- Havel RJ: Biology of cholesterol, lipoproteins and atherosclerosis. Clin Exp Hypertens A. 1989, 11 (5–6): 887-900.
- Brown AJ: Atherosclerosis: cell biology and lipoproteins: cholesterol absorption inhibitors: gateway therapy for hypercholesterolaemia. Curr Opin Lipidol. 2002, 13 (6): 701-703. 10.1097/00041433-200212000-00016.View Article
- Bosner MS, Lange LG, Stenson WF, Ostlund RE: Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J Lipid Res. 1999, 40 (2): 302-308.
- Hui DY, Howles PN: Molecular mechanisms of cholesterol absorption and transport in the intestine. Semin Cell Dev Biol. 2005, 16 (2): 183-192. 10.1016/j.semcdb.2005.01.003.View Article
- Hernell O, Staggers JE, Carey MC: Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. Biochemistry. 1990, 29 (8): 2041-2056. 10.1021/bi00460a012.View Article
- Westergaard H, Dietschy JM: The mechanism whereby bile acid micelles increase the rate of fatty acid and cholesterol uptake into the intestinal mucosal cell. J Clin Invest. 1976, 58 (1): 97-108. 10.1172/JCI108465.View Article
- Chijiiwa K, Linscheer WG: Distribution and monomer activity of cholesterol in micellar bile salt: effect of cholesterol level. Am J Physiol. 1987, 252 (3 Pt 1): G309-G314.
- Hauser H, Dyer JH, Nandy A, Vega MA, Werder M, Bieliauskaite E, Weber FE, Compassi S, Gemperli A, Boffelli D, et al.: Identification of a receptor mediating absorption of dietary cholesterol in the intestine. Biochemistry. 1998, 37 (51): 17843-17850. 10.1021/bi982404y.View Article
- Detmers PA, Patel S, Hernandez M, Montenegro J, Lisnock JM, Pikounis B, Steiner M, Kim D, Sparrow C, Chao YS, et al.: A target for cholesterol absorption inhibitors in the enterocyte brush border membrane. Biochim Biophys Acta. 2000, 1486 (2–3): 243-252.View Article
- Voshol PJ, Schwarz M, Rigotti A, Krieger M, Groen AK, Kuipers F: Down-regulation of intestinal scavenger receptor class B, type I (SR-BI) expression in rodents under conditions of deficient bile delivery to the intestine. Biochem J. 2001, 356 (Pt 2): 317-325.View Article
- Mahley RW, Innerarity TL: Lipoprotein receptors and cholesterol homeostasis. Biochim Biophys Acta. 1983, 737 (2): 197-222. 10.1016/0304-4157(83)90001-1.View Article
- Havel RJ: Postprandial lipid metabolism: an overview. Proc Nutr Soc. 1997, 56 (2): 659-666. 10.1079/PNS19970065.View Article
- Spady DK, Turley SD, Dietschy JM: Rates of low density lipoprotein uptake and cholesterol synthesis are regulated independently in the liver. J Lipid Res. 1985, 26 (4): 465-472.
- St-Pierre MV, Kullak-Ublick GA, Hagenbuch B, Meier PJ: Transport of bile acids in hepatic and non-hepatic tissues. J Exp Biol. 2001, 204 (Pt 10): 1673-1686.
- Hofmann AF: Bile Acids: The Good, the Bad, and the Ugly. News Physiol Sci. 1999, 14: 24-29.
- Olivecrona G, Olivecrona T: Triglyceride lipases and atherosclerosis. Curr Opin Lipidol. 1995, 6 (5): 291-305. 10.1097/00041433-199510000-00009.View Article
- Packard CJ, Shepherd J: Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 1997, 17 (12): 3542-3556. 10.1161/01.ATV.17.12.3542.View Article
- Hussain MM, Strickland DK, Bakillah A: The mammalian low-density lipoprotein receptor family. Annu Rev Nutr. 1999, 19: 141-172. 10.1146/annurev.nutr.19.1.141.View Article
- Willnow TE, Nykjaer A, Herz J: Lipoprotein receptors: new roles for ancient proteins. Nat Cell Biol. 1999, 1 (6): E157-E162. 10.1038/14109.View Article
- Brown MS, Goldstein JL: Sterol regulatory element binding proteins (SREBPs): controllers of lipid synthesis and cellular uptake. Nutr Rev. 1998, 56 (2 Pt 2): S1-S3. discussion S54-75
- Small DM: Mechanisms of reversed cholesterol transport. Agents Actions Suppl. 1988, 26: 135-146.
- Fielding CJ, Fielding PE: Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995, 36 (2): 211-228.
- Groen AK, Oude Elferink RP, Verkade HJ, Kuipers F: The ins and outs of reverse cholesterol transport. Ann Med. 2004, 36 (2): 135-145. 10.1080/07853890310020635.View Article
- Johnson WJ, Mahlberg FH, Rothblat GH, Phillips MC: Cholesterol transport between cells and high-density lipoproteins. Biochim Biophys Acta. 1991, 1085 (3): 273-298. 10.1016/0005-2760(91)90132-2.View Article
- Lewis GF, Rader DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005, 96 (12): 1221-1232. 10.1161/01.RES.0000170946.56981.5c.View Article
- Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science. 1986, 232 (4746): 34-47. 10.1126/science.3513311.View Article
- Brown MS, Goldstein JL: A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A. 1999, 96 (20): 11041-11048. 10.1073/pnas.96.20.11041.View Article
- Miettinen TA, Gylling H: Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur J Clin Invest. 2003, 33 (11): 976-982. 10.1046/j.1365-2362.2003.01229.x.View Article
- Watts GF, Chan DC, Barrett PH, O'Neill FH, Thompson GR: Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int J Obes Relat Metab Disord. 2003, 27 (7): 862-865. 10.1038/sj.ijo.0802287.View Article
- Grundy SM, Vega GL, Bilheimer DW: Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia. Ann Intern Med. 1985, 103 (3): 339-343.View Article
- Ericsson S, Eriksson M, Vitols S, Einarsson K, Berglund L, Angelin B: Influence of age on the metabolism of plasma low density lipoproteins in healthy males. J Clin Invest. 1991, 87 (2): 591-596. 10.1172/JCI115034.View Article
- Millar JS, Lichtenstein AH, Cuchel M, Dolnikowski GG, Hachey DL, Cohn JS, Schaefer EJ: Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men. J Lipid Res. 1995, 36 (6): 1155-1167.
- Uchida K, Chikai T, Takase H, Nomura Y, Seo S, Nakao H, Takeuchi N: Age-related changes of bile acid metabolism in rats. Arch Gerontol Geriatr. 1990, 10 (1): 37-48. 10.1016/0167-4943(90)90042-5.View Article
- McNamara DJ: The impact of egg limitations on coronary heart disease risk: do the numbers add up?. J Am Coll Nutr. 2000, 19 (5 Suppl): 540S-548S.View Article
- Knoblauch H, Schuster H, Luft FC, Reich J: A pathway model of lipid metabolism to predict the effect of genetic variability on lipid levels. J Mol Med (Berl). 2000, 78 (9): 507-515. 10.1007/s001090000156.View Article
- Chun PW, Espinosa AJ, Lee CW, Shireman RB, Brumbaugh EE: Low density lipoprotein receptor regulation. Kinetic models. Biophys Chem. 1985, 21 (3–4): 185-209.View Article
- Wattis JA, O'Malley B, Blackburn H, Pickersgill L, Panovska J, Byrne HM, Jackson KG: Mathematical model for low density lipoprotein (LDL) endocytosis by hepatocytes. Bull Math Biol. 2008, 70 (8): 2303-2333. 10.1007/s11538-008-9347-9.View Article
- Adiels M, Packard C, Caslake MJ, Stewart P, Soro A, Westerbacka J, Wennberg B, Olofsson SO, Taskinen MR, Boren J: A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. J Lipid Res. 2005, 46 (1): 58-67.View Article
- Erkkila AT, Lichtenstein AH: Fiber and cardiovascular disease risk: how strong is the evidence?. J Cardiovasc Nurs. 2006, 21 (1): 3-8.View Article
- Brown L, Rosner B, Willett WW, Sacks FM: Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999, 69 (1): 30-42.
- Lees AM, Mok HY, Lees RS, McCluskey MA, Grundy SM: Plant sterols as cholesterol-lowering agents: clinical trials in patients with hypercholesterolemia and studies of sterol balance. Atherosclerosis. 1977, 28 (3): 325-338. 10.1016/0021-9150(77)90180-0.View Article
- Mattson FH, Volpenhein RA, Erickson BA: Effect of plant sterol esters on the absorption of dietary cholesterol. J Nutr. 1977, 107 (7): 1139-1146.
- Law M: Plant sterol and stanol margarines and health. BMJ. 2000, 320 (7238): 861-864. 10.1136/bmj.320.7238.861.View Article
- Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R: Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc. 2003, 78 (8): 965-978.View Article
- St-Onge MP, Jones PJ: Phytosterols and human lipid metabolism: efficacy, safety, and novel foods. Lipids. 2003, 38 (4): 367-375. 10.1007/s11745-003-1071-3.View Article
- Scheer M, Grote A, Chang A, Schomburg I, Munaretto C, Rother M, Sohngen C, Stelzer M, Thiele J, Schomburg D: BRENDA, the enzyme information system in 2011. Nucleic Acids Res. 2011, 39 (Database issue): D670-D676.View Article
- Cobbold CA, Sherratt JA, Maxwell SR: Lipoprotein oxidation and its significance for atherosclerosis: a mathematical approach. Bull Math Biol. 2002, 64 (1): 65-95. 10.1006/bulm.2001.0267.View Article
- Krause F, Uhlendorf J, Lubitz T, Schulz M, Klipp E, Liebermeister W: Annotation and merging of SBML models with semanticSBML. Bioinformatics. 2010, 26 (3): 421-422. 10.1093/bioinformatics/btp642.View Article
- Schulz M, Uhlendorf J, Klipp E, Liebermeister W: SBMLmerge, a system for combining biochemical network models. Genome Inform. 2006, 17 (1): 62-71.
- Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991, 88 (6): 1785-1792. 10.1172/JCI115499.View Article
- Steinberg D: Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997, 272 (34): 20963-20966. 10.1074/jbc.272.34.20963.View Article
- Heijmans BT, Beekman M, Houwing-Duistermaat JJ, Cobain MR, Powell J, Blauw GJ, van der Ouderaa F, Westendorp RG, Slagboom PE: Lipoprotein particle profiles mark familial and sporadic human longevity. PLoS Med. 2006, 3 (12): e495-10.1371/journal.pmed.0030495.View Article
- Rahilly-Tierney CR, Spiro A, Vokonas P, Gaziano JM: Relation between high-density lipoprotein cholesterol and survival to age 85 years in men (from the VA normative aging study). Am J Cardiol. 2011, 107 (8): 1173-1177. 10.1016/j.amjcard.2010.12.015.View Article
- Goldstein B, Wofsy C, Bell G: Interactions of low density lipoprotein receptors with coated pits on human fibroblasts: estimate of the forward rate constant and comparison with the diffusion limit. Proc Natl Acad Sci U S A. 1981, 78 (9): 5695-5698. 10.1073/pnas.78.9.5695.View Article
- Keizer J, Ramirez J, Peacock-Lopez E: The effect of diffusion on the binding of membrane-bound receptors to coated pits. Biophys J. 1985, 47 (1): 79-87. 10.1016/S0006-3495(85)83879-0.View Article
- Gao H, Shi W, Freund LB: Mechanics of receptor-mediated endocytosis. Proc Natl Acad Sci U S A. 2005, 102 (27): 9469-9474. 10.1073/pnas.0503879102.View Article
- Pont F, Duvillard L, Verges B, Gambert P: Development of compartmental models in stable-isotope experiments: application to lipid metabolism. Arterioscler Thromb Vasc Biol. 1998, 18 (6): 853-860. 10.1161/01.ATV.18.6.853.View Article
- Le Novere N, Hucka M, Mi H, Moodie S, Schreiber F, Sorokin A, Demir E, Wegner K, Aladjem MI, Wimalaratne SM, et al.: The systems biology graphical notation. Nat Biotechnol. 2009, 27 (8): 735-741. 10.1038/nbt.1558.View Article
- Shapiro BE, Hucka M, Finney A, Doyle J: MathSBML: a package for manipulating SBML-based biological models. Bioinformatics. 2004, 20 (16): 2829-2831. 10.1093/bioinformatics/bth271.View Article
- Wolfram Research I: Mathematica Edition: Version 5.2. 2005, Champaign, Illinois: Wolfram Research Inc
- Mendes P, Hoops S, Sahle S, Gauges R, Dada J, Kummer U: Computational modeling of biochemical networks using COPASI. Methods Mol Biol. 2009, 500: 17-59. 10.1007/978-1-59745-525-1_2.View Article
- Henderson LG, Gregory J, Irving K, Swan G: National diet and Nutrtion Survey (NDNS) of adults aged 19 to 64. 2003, 70-2
- Dietschy JM, Turley SD, Spady DK: Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993, 34 (10): 1637-1659.
- Dietschy JM: Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. Am J Clin Nutr. 1997, 65 (5 Suppl): 1581S-1589S.
- Grundy SM, Metzger AL: A physiological method for estimation of hepatic secretion of biliary lipids in man. Gastroenterology. 1972, 62 (6): 1200-1217.
- Soars MG, Burchell B, Riley RJ: In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther. 2002, 301 (1): 382-390. 10.1124/jpet.301.1.382.View Article
- Redinger RN: The coming of age of our understanding of the enterohepatic circulation of bile salts. Am J Surg. 2003, 185 (2): 168-172. 10.1016/S0002-9610(02)01212-6.View Article
- Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002, 106 (15): 1943-1948. 10.1161/01.CIR.0000034044.95911.DC.View Article
- Sahlin S, Granstrom L, Gustafsson U, Stahlberg D, Backman L, Einarsson K: Hepatic esterification rate of cholesterol and biliary lipids in human obesity. J Lipid Res. 1994, 35 (3): 484-490.
- Cook R: Distribution of sterols in organisms and in tissues. Chemistry, biochemistry, and pathology. 1958, New York: Academic Press Inc
- Erickson SK, Bosterling B: Cholesterol 7 alpha-hydroxylase from human liver: partial purification and reconstruction into defined phospholipid-cholesterol vesicles. J Lipid Res. 1981, 22 (5): 872-876.
- Glomset JA, Norum KR: The metabolic role of lecithin: cholesterol acyltransferase: perspectives form pathology. Adv Lipid Res. 1973, 11: 1-65.
- Brown MS, Goldstein JL: Receptor-mediated control of cholesterol metabolism. Science. 1976, 191 (4223): 150-154. 10.1126/science.174194.View Article
- August E, Parker KH, Barahona M: A dynamical model of lipoprotein metabolism. Bull Math Biol. 2007, 69 (4): 1233-1254. 10.1007/s11538-006-9132-6.View Article
- Yamada N, Shames DM, Stoudemire JB, Havel RJ: Metabolism of lipoproteins containing apolipoprotein B-100 in blood plasma of rabbits: heterogeneity related to the presence of apolipoprotein E. Proc Natl Acad Sci U S A. 1986, 83 (10): 3479-3483. 10.1073/pnas.83.10.3479.View Article
- Spady DK, Bilheimer DW, Dietschy JM: Rates of receptor-dependent and -independent low density lipoprotein uptake in the hamster. Proc Natl Acad Sci U S A. 1983, 80 (11): 3499-3503. 10.1073/pnas.80.11.3499.View Article
- Spady DK, Meddings JB, Dietschy JM: Kinetic constants for receptor-dependent and receptor-independent low density lipoprotein transport in the tissues of the rat and hamster. J Clin Invest. 1986, 77 (5): 1474-1481. 10.1172/JCI112460.View Article
- Spady DK, Huettinger M, Bilheimer DW, Dietschy JM: Role of receptor-independent low density lipoprotein transport in the maintenance of tissue cholesterol balance in the normal and WHHL rabbit. J Lipid Res. 1987, 28 (1): 32-41.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.